Servier’s late 2020 decision to pay $1.8bn for Agios Pharmaceuticals, Inc.’ cancer portfolio appears to be paying off handsomely with the lead investigational product from that transaction, vorasidenib, looking set to provide the first targeted treatment for low-grade glioma.
Full data from the Phase III INDIGO presented at the American Society of Clinical Oncology meeting in Chicago on 4 June show that it produced a near 2
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?